Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjunctive rufinamide in pediatric Lennox-Gastaut syndrome (1 to <4 years)
2010-023505-36Phase 3
- Sponsor
- Eisai Co., Ltd.
- Start
- May 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rufinamide in Lennox-Gastaut syndrome (LGS) (2 arms), sponsored by Eisai Co., Ltd.
02
Drugs
rufinamide
03
Conditions
Lennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on 2010-023505-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023505-36.